Pharmaceuticals, Biotechnology and Life Sciences
If approved, the vaccine will help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and…
The UK has approved Pfizer’s COVID-19 vaccine on Wednesday, becoming the first country in the world to do so, going ahead of the United States and the EU countries, who expect to bring the decisions on authorization in December.
Pfizer’s and Biontech’s vaccine candidate for COVID-19 has met all the study’s primary efficacy endpoints.
Pfizer says its vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…
ViiV Healthcare Friday said that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, used combined with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain young patients.
Pfizer’s 20vPnC vaccine candidate in Pahse 3 study showed responses elicited by 20vPnC for all 20 serotypes equivalent across all three lots, meeting the primary immunogenicity objective of the study.
Pfizer invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
First-Quarter 2020 Revenues of $12.0 Billion, Reflecting 7% Operational Decline; Excluding the Impact from Consumer Healthcare(1), Revenues Declined 1% Operationally.